Wikipedia

Lipopolysaccharide

This is an old revision of this page, as edited by Tsarivan613 (talk | contribs) at 22:41, 22 August 2024 (Copy edit per MOS:NUMERAL). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Not to be confused with glycolipid.

Lipopolysaccharide, now more commonly known as Endotoxin,[1] is a collective term for components of the outermost membrane of cell envelope of Gram-negative bacteria, such as E. coli and Salmonella.[2] with a common structural architecture. Lipopolysaccharides (LPS) are large molecules consisting of three parts: an outer core polysaccharide termed the O-antigen, an inner core oligosaccharide and Lipid A (from which toxicity is largely derived), all covalently linked. In current terminology, the term endotoxin is often used synonymously with LPS, although there are a few endotoxins (in the original sense of toxins that are inside the bacterial cell that are released when the cell disintegrates) that are not related to LPS, such as the so-called delta endotoxin proteins produced by Bacillus thuringiensis.[3]

Structure of a lipopolysaccharide (LPS)

Lipopolysaccharides can have substantial impacts on human health, primarily through interactions with the immune system. LPS is a potent activator of the immune system and is a pyrogen (agent that causes fever).[4] In severe cases, LPS can trigger a brisk host response and multiple types of acute organ failure [5] which can lead to septic shock.[6] In lower levels and over a longer time period, there is evidence LPS may play an important and harmful role in autoimmunity, obesity, depression, and cellular senescence.[7][8][9][10]

Discovery

The toxic activity of LPS was first discovered and termed endotoxin by Richard Friedrich Johannes Pfeiffer. He distinguished between exotoxins, toxins that are released by bacteria into the surrounding environment, and endotoxins, which are toxins "within" the bacterial cell and released only after destruction of the bacterial outer membrane.[11] Subsequent work showed that release of LPS from Gram negative microbes does not necessarily require the destruction of the bacterial cell wall, but rather, LPS is secreted as part of the normal physiological activity of membrane vesicle trafficking in the form of bacterial outer membrane vesicles (OMVs), which may also contain other virulence factors and proteins.[12][2]

Functions in bacteria

LPS is a major component of the outer cell membrane of Gram-negative bacteria, contributing greatly to the structural integrity of the bacteria and protecting the membrane from certain kinds of chemical attack. LPS is the most abundant antigen on the cell surface of most Gram-negative bacteria, contributing up to 80% of the outer membrane of E. coli and Salmonella.[2] LPS increases the negative charge of the cell membrane and helps stabilize the overall membrane structure. It is of crucial importance to many Gram-negative bacteria, which die if the genes coding for it are mutated or removed. However, it appears that LPS is nonessential in at least some Gram-negative bacteria, such as Neisseria meningitidis, Moraxella catarrhalis, and Acinetobacter baumannii.[13] It has also been implicated in non-pathogenic aspects of bacterial ecology, including surface adhesion, bacteriophage sensitivity, and interactions with predators such as amoebae. LPS is also required for the functioning of omptins, a class of bacterial protease.[14]

Composition

 
The saccharolipid Kdo2-Lipid A. Kdo residues in red (core), glucosamine residues in blue, acyl chains in black and phosphate groups in green.

LPS are amphipathic and composed of three parts: the O antigen (or O polysaccharide) which is hydrophilic, the core oligosaccharide (also hydrophilic), and Lipid A, the hydrophobic domain.

O-antigen

The repetitive glycan polymer contained within an LPS is referred to as the O antigen, O polysaccharide, or O side-chain of the bacteria. The O antigen is attached to the core oligosaccharide, and comprises the outermost domain of the LPS molecule. The structure and composition of the O chain is highly variable from strain to strain, determining the serological specificity of the parent bacterial strain;[15] there are over 160 different O antigen structures produced by different E. coli strains.[16] The presence or absence of O chains determines whether the LPS is considered "rough" or "smooth". Full-length O-chains would render the LPS smooth, whereas the absence or reduction of O-chains would make the LPS rough.[17] Bacteria with rough LPS usually have more penetrable cell membranes to hydrophobic antibiotics, since a rough LPS is more hydrophobic.[18] O antigen is exposed on the very outer surface of the bacterial cell, and, as a consequence, is a target for recognition by host antibodies.

Core

Main article: Core oligosaccharide

The core domain always contains an oligosaccharide component that attaches directly to lipid A and commonly contains sugars such as heptose and 3-Deoxy-D-manno-oct-2-ulosonic acid (also known as KDO, keto-deoxyoctulosonate).[19] The core oligosaccharide is less variable in its structure and composition, a given core structure being common to large groups of bacteria.[15] The LPS cores of many bacteria also contain non-carbohydrate components, such as phosphate, amino acids, and ethanolamine substituents.

Lipid A

Main article: Lipid A

Lipid A is, in normal circumstances, a phosphorylated glucosamine disaccharide decorated with multiple fatty acids. These hydrophobic fatty acid chains anchor the LPS into the bacterial membrane, and the rest of the LPS projects from the cell surface. The lipid A domain is the most bioactive and responsible for much of the toxicity of Gram-negative bacteria. When bacterial cells are lysed by the immune system, fragments of membrane containing lipid A may be released into the circulation, causing fever, diarrhea, and possible fatal endotoxic septic shock (a form of septic shock). The Lipid A moiety is a very conserved component of the LPS.[20] However Lipid A structure varies among bacterial species. Lipid A structure largely defines the degree and nature of the overall host immune activation.[21]

Lipooligosaccharides

The "rough form" of LPS has a lower molecular weight due to the absence of the O polysaccharide. In its place is a short oligosaccharide: this form is known as Lipooligosaccharide (LOS), and is a glycolipid found in the outer membrane of some types of Gram-negative bacteria, such as Neisseria spp. and Haemophilus spp.[7][22] LOS plays a central role in maintaining the integrity and functionality of the outer membrane of the Gram negative cell envelope. LOS play an important role in the pathogenesis of certain bacterial infections because they are capable of acting as immunostimulators and immunomodulators.[7] Furthermore, LOS molecules are responsible for the ability of some bacterial strains to display molecular mimicry and antigenic diversity, aiding in the evasion of host immune defenses and thus contributing to the virulence of these bacterial strains. In the case of Neisseria meningitidis, the lipid A portion of the molecule has a symmetrical structure and the inner core is composed of 3-deoxy-D-manno-2-octulosonic acid (KDO) and heptose (Hep) moieties. The outer core oligosaccharide chain varies depending on the bacterial strain.[7][22]

LPS detoxification

A highly conserved host enzyme called acyloxyacyl hydrolase (AOAH) may detoxify LPS when it enters, or is produced in, animal tissues. It may also convert LPS in the intestine into an LPS inhibitor. Neutrophils, macrophages and dendritic cells produce this lipase, which inactivates LPS by removing the two secondary acyl chains from lipid A to produce tetraacyl LPS. If mice are given LPS parenterally, those that lack AOAH develop high titers of non-specific antibodies, develop prolonged hepatomegaly, and experience prolonged endotoxin tolerance. LPS inactivation may be required for animals to restore homeostasis after parenteral LPS exposure.[23] Although mice have many other mechanisms for inhibiting LPS signaling, none is able to prevent these changes in animals that lack AOAH.

Dephosphorylation of LPS by intestinal alkaline phosphatase can reduce the severity of Salmonella tryphimurium and Clostridioides difficile infection restoring normal gut microbiota.[24] Alkaline phosphatase prevents intestinal inflammation (and "leaky gut") from bacteria by dephosphorylating the Lipid A portion of LPS.[25][26][27]

Biosynthesis and transport

 
LPS final assembly: O-antigen subunits are translocated across the inner membrane (by Wzx) where they are polymerized (by Wzy, chain length determined by Wzz) and ligated (by WaaL) on to complete Core-Lipid A molecules (which were translocated by MsbA).[28]
 
LPS transport: Completed LPS molecules are transported across the periplasm and outer membrane by the lipopolysaccharide transport (Lpt) proteins A, B, C, D, E, F, and G.[29]

The entire process of making LPS starts with a molecule called lipid A-Kdo2, which is first created on the surface of the bacterial cell's inner membrane. Then, additional sugars are added to this molecule on the inner membrane before it's moved to the space between the inner and outer membranes (periplasmic space) with the help of a protein called MsbA. The O-antigen, another part of LPS, is made by special enzyme complexes on the inner membrane. It is then moved to the outer membrane through three different systems: one is Wzy-dependent, another relies on ABC transporters, and the third involves a synthase-dependent process.[30]

Ultimately, LPS is transported to the outer membrane by a membrane-to-membrane bridge of lipolysaccharide transport (Lpt) proteins.[29][31] This transporter is a potential antibiotic target.[32][33]

Biological effects on hosts infected with Gram-negative bacteria

LPS storage in the body

The human body carries endogenous stores on LPS.[34] The epithelial surfaces are colonized by a complex microbial flora (including gram-negative bacteria), which outnumber human cells by a factor of 10 to 1. Gram-negative bacterial will shed endotoxins. This host-microbial interaction is a symbiotic relationship which plays a critical role in systemic immunologic homeostasis. When this is disrupted, it can lead to disease such as endotoxemia and endotoxic septic shock.

Immune response

LPS acts as the prototypical endotoxin because it binds the CD14/TLR4/MD2 receptor complex in many cell types, but especially in monocytes, dendritic cells, macrophages and B cells, which promotes the secretion of pro-inflammatory cytokines, nitric oxide, and eicosanoids.[35] Bruce Beutler was awarded a portion of the 2011 Nobel Prize in Physiology or Medicine for his work demonstrating that TLR4 is the LPS receptor.[36][37]

As part of the cellular stress response, superoxide is one of the major reactive oxygen species induced by LPS in various cell types that express TLR (toll-like receptor).[38] LPS is also an exogenous pyrogen (fever-inducing substance).[4]

LPS function has been under experimental research for several years due to its role in activating many transcription factors. LPS also produces many types of mediators involved in septic shock. Of mammals, humans are much more sensitive to LPS than other primates,[39] and other animals as well (e.g., mice). A dose of 1 μg/kg induces shock in humans, but mice will tolerate a dose up to a thousand times higher.[40] This may relate to differences in the level of circulating natural antibodies between the two species.[41][42] It may also be linked to multiple immune tactics against pathogens, and part of a multi-faceted anti-microbial strategy that has been informed by human behavioral changes over our species' evolution (e.g., meat eating, agricultural practices, and smoking).[39] Said et al. showed that LPS causes an IL-10-dependent inhibition of CD4 T-cell expansion and function by up-regulating PD-1 levels on monocytes which leads to IL-10 production by monocytes after binding of PD-1 by PD-L1.[43]

Endotoxins are in large part responsible for the dramatic clinical manifestations of infections with pathogenic Gram-negative bacteria, such as Neisseria meningitidis, the pathogens that causes meningococcal disease, including meningococcemia, Waterhouse–Friderichsen syndrome, and meningitis.

Portions of the LPS from several bacterial strains have been shown to be chemically similar to human host cell surface molecules; the ability of some bacteria to present molecules on their surface which are chemically identical or similar to the surface molecules of some types of host cells is termed molecular mimicry.[44] For example, in Neisseria meningitidis L2,3,5,7,9, the terminal tetrasaccharide portion of the oligosaccharide (lacto-N-neotetraose) is the same tetrasaccharide as that found in paragloboside, a precursor for ABH glycolipid antigens found on human erythrocytes.[7] In another example, the terminal trisaccharide portion (lactotriaose) of the oligosaccharide from pathogenic Neisseria spp. LOS is also found in lactoneoseries glycosphingolipids from human cells.[7] Most meningococci from groups B and C, as well as gonococci, have been shown to have this trisaccharide as part of their LOS structure.[7] The presence of these human cell surface 'mimics' may, in addition to acting as a 'camouflage' from the immune system, play a role in the abolishment of immune tolerance when infecting hosts with certain human leukocyte antigen (HLA) genotypes, such as HLA-B35.[7]

LPS can be sensed directly by hematopoietic stem cells (HSCs) through the bonding with TLR4, causing them to proliferate in reaction to a systemic infection. This response activate the TLR4-TRIF-ROS-p38 signaling within the HSCs and through a sustained TLR4 activation can cause a proliferative stress, leading to impair their competitive repopulating ability.[45] Infection in mice using S. typhimurium showed similar results, validating the experimental model also in vivo.

Effect of variability on immune response

 
Toll-like receptors of the innate immune system recognize LPS and trigger an immune response.

O-antigens (the outer carbohydrates) are the most variable portion of the LPS molecule, imparting antigenic specificity. In contrast, lipid A is the most conserved part. However, lipid A composition also may vary (e.g., in number and nature of acyl chains even within or between genera). Some of these variations may impart antagonistic properties to these LPS. For example, diphosphoryl lipid A of Rhodobacter sphaeroides (RsDPLA) is a potent antagonist of LPS in human cells, but is an agonist in hamster and equine cells.[46]

It has been speculated that conical lipid A (e.g., from E. coli) is more agonistic, while less conical lipid A like that of Porphyromonas gingivalis may activate a different signal (TLR2 instead of TLR4), and completely cylindrical lipid A like that of Rhodobacter sphaeroides is antagonistic to TLRs.[47][48] In general, LPS gene clusters are highly variable between different strains, subspecies, species of bacterial pathogens of plants and animals.[49][50]

Normal human blood serum contains anti-LOS antibodies that are bactericidal and patients that have infections caused by serotypically distinct strains possess anti-LOS antibodies that differ in their specificity compared with normal serum.[51] These differences in humoral immune response to different LOS types can be attributed to the structure of the LOS molecule, primarily within the structure of the oligosaccharide portion of the LOS molecule.[51] In Neisseria gonorrhoeae it has been demonstrated that the antigenicity of LOS molecules can change during an infection due to the ability of these bacteria to synthesize more than one type of LOS,[51] a characteristic known as phase variation. Additionally, Neisseria gonorrhoeae, as well as Neisseria meningitidis and Haemophilus influenzae,[7] are capable of further modifying their LOS in vitro, for example through sialylation (modification with sialic acid residues), and as a result are able to increase their resistance to complement-mediated killing [51] or even down-regulate complement activation[7] or evade the effects of bactericidal antibodies.[7] Sialylation may also contribute to hindered neutrophil attachment and phagocytosis by immune system cells as well as a reduced oxidative burst.[7] Haemophilus somnus, a pathogen of cattle, has also been shown to display LOS phase variation, a characteristic which may help in the evasion of bovine host immune defenses.[52] Taken together, these observations suggest that variations in bacterial surface molecules such as LOS can help the pathogen evade both the humoral (antibody and complement-mediated) and the cell-mediated (killing by neutrophils, for example) host immune defenses.

Non-canonical pathways of LPS recognition

Recently, it was shown that in addition to TLR4 mediated pathways, certain members of the family of the transient receptor potential ion channels recognize LPS.[53] LPS-mediated activation of TRPA1 was shown in mice[54] and Drosophila melanogaster flies.[55] At higher concentrations, LPS activates other members of the sensory TRP channel family as well, such as TRPV1, TRPM3 and to some extent TRPM8.[56] LPS is recognized by TRPV4 on epithelial cells. TRPV4 activation by LPS was necessary and sufficient to induce nitric oxide production with a bactericidal effect.[57]

Testing

Lipopolysaccharide is a significant factor that makes bacteria harmful, and it helps categorize them into different groups based on their structure and function. This makes LPS a useful marker for telling apart various Gram-negative bacteria. Swiftly identifying and understanding the types of pathogens involved is crucial for promptly managing and treating infections. Since LPS is the main trigger for the immune response in our cells, it acts as an early signal of an acute infection. Therefore, LPS testing is more specific and meaningful than many other serological tests.[58]

The current methods for testing LPS are quite sensitive, but many of them struggle to differentiate between different LPS groups. Additionally, the nature of LPS, which has both water-attracting and water-repelling properties (amphiphilic), makes it challenging to develop sensitive and user-friendly tests.[58]

The typical detection methods rely on identifying the lipid A part of LPS because Lipid A is very similar among different bacterial species and serotypes. LPS testing techniques fall into six categories, and they often overlap: in vivo tests, in vitro tests, modified immunoassays, biological assays, and chemical assays.[58]

Endotoxin Activity Assay

Because the LPS is very difficult to measure in whole blood and because most LPS is bound to proteins and complement, the Endotoxin Activity Assay (EAA™) was developed and cleared by the US FDA in 2003. EAA is a rapid in vitro chemiluminescent immunodiagnostic test. It utilizes a specific monoclonal antibody to measure the endotoxin activity in EDTA whole blood specimens. This assay uses the biological response of the neutrophils in a patient’s blood to an immunological complex of endotoxin and exogenous antibody – the chemiluminescent reaction formed creates an emission of light. The amount of chemiluminescence is proportional to the logarithmic concentration of LPS in the sample and is a measure of the endotoxin activity in the blood.[59] The assay reacts specifically with the Lipid A moiety of LPS of Gram-negative bacteria and does not cross-react with cell wall constituents of Gram-positive bacteria and other microorganisms.

Pathophysiology

LPS is a powerful toxin that, when in the body, triggers inflammation by binding to cell receptors. Excessive LPS in the blood, endotoxemia, may cause a highly lethal form of sepsis known as endotoxic septic shock.[5] This condition includes symptoms that fall along a continuum of pathophysiologic states, starting with a systemic inflammatory response syndrome (SIRS) and ending in multiorgan dysfunction syndrome (MODS) before death. Early symptoms include rapid heart rate, quick breathing, temperature changes, and blood clotting issues, resulting in blood vessels widening and reduced blood volume, leading to cellular dysfunction.[58]

Recent research indicates that even small LPS exposure is associated with autoimmune diseases and allergies. High levels of LPS in the blood can lead to metabolic syndrome, increasing the risk of conditions like diabetes, heart disease, and liver problems.[58]

LPS also plays a crucial role in symptoms caused by infections from harmful bacteria, including severe conditions like Waterhouse-Friderichsen syndrome, meningococcemia, and meningitis. Certain bacteria can adapt their LPS to cause long-lasting infections in the respiratory and digestive systems.[58]

Recent studies have shown that LPS disrupts cell membrane lipids, affecting cholesterol and metabolism, potentially leading to high cholesterol, abnormal blood lipid levels, and non-alcoholic fatty liver disease. In some cases, LPS can interfere with toxin clearance, which may be linked to neurological issues.[58]

Health effects

In general the health effects of LPS are due to its abilities as a potent activator and modulator of the immune system, especially its inducement of inflammation. LPS is directly cytoxic and is highly immunostimulatory – as host immune cells recognize LPS, complement are strongly activated. Complement activation and a rising anti-inflammatory response can lead to immune cell dysfunction, immunosuppression, widespread coagulopathy, serious tissue damage and can progress to multi-system organ failure and death.[39]

Endotoxemia

The presence of endotoxins in the blood is called endotoxemia. High level of endotoxemia can lead to septic shock,[60] or more specifically endotoxic septic shock,[5] while lower concentration of endotoxins in the bloodstream is called metabolic endotoxemia.[61] Endotoxemia is associated with obesity, diet,[62] cardiovascular diseases,[62] and diabetes,[61] while also host genetics might have an effect.[63]

Moreover, endotoxemia of intestinal origin, especially, at the host-pathogen interface, is considered to be an important factor in the development of alcoholic hepatitis,[64] which is likely to develop on the basis of the small bowel bacterial overgrowth syndrome and an increased intestinal permeability.[65]

Lipid A may cause uncontrolled activation of mammalian immune systems with production of inflammatory mediators that may lead to endotoxic septic shock.[22][5] This inflammatory reaction is primarily mediated by Toll-like receptor 4 which is responsible for immune system cell activation.[22] Damage to the endothelial layer of blood vessels caused by these inflammatory mediators can lead to capillary leak syndrome, dilation of blood vessels and a decrease in cardiac function and can further worsen shock.[66] LPS is also a potent activator of complemen.[66] Uncontrolled complement activation may trigger destructive endothelial damage leading to disseminated intravascular coagulation (DIC), or atypical hemolytic uremic syndrome (aHUS) with injury to various organs such as including kidneys and lungs.[67] The skin can show the effects of vascular damage often coupled with depletion of coagulation factors in the form of petechiae, purpura and ecchymoses. The limbs can also be affected, sometimes with devastating consequences such as the development of gangrene, requiring subsequent amputation.[66] Loss of function of the adrenal glands can cause adrenal insufficiency and additional hemorrhage into the adrenals causes Waterhouse-Friderichsen syndrome, both of which can be life-threatening.

It has also been reported that gonococcal LOS can cause damage to human fallopian tubes.[51]

Treatment of Endotoxemia

Toraymyxin© (Toray, Tokyo, Japan) is a widely used extracorporeal endotoxin removal therapy through direct hemoadsorption (also referred to as hemoperfusion). It is a polystyrene-derived cartridge with molecules of polymyxin B (PMX-B) covalently bound to mesh fibers contained within it. Polymyxins are cyclic cationic polypeptide antibiotics derived from Bacillus polymyxa with an effective antimicrobial activity against Gram-negative bacteria, but their intravenous clinical use has been limited due to their nephrotoxicity and neurotoxicity side effects.[68] The extracorporeal use of the Toraymyxin© cartridge allows PMX-B to bind lipid A with a very stable interaction with its hydrophobic residues thereby neutralizing endotoxins as the blood is filtered through the extracorporeal circuit inside the cartridge, thus reversing endotoxemia and avoiding its toxic systemic effects.[69]

Auto-immune disease

The molecular mimicry of some LOS molecules is thought to cause autoimmune-based host responses, such as flareups of multiple sclerosis.[7][44] Other examples of bacterial mimicry of host structures via LOS are found with the bacteria Helicobacter pylori and Campylobacter jejuni, organisms which cause gastrointestinal disease in humans, and Haemophilus ducreyi which causes chancroid. Certain C. jejuni LPS serotypes (attributed to certain tetra- and pentasaccharide moieties of the core oligosaccharide) have also been implicated with Guillain–Barré syndrome and a variant of Guillain–Barré called Miller-Fisher syndrome.[7]

Epidemiological studies have shown that increased endotoxin load, which can be a result of increased populations of endotoxin-producing bacteria in the intestinal tract, is associated with certain obesity-related patient groups.[8][70][71] Other studies have shown that purified endotoxin from Escherichia coli can induce obesity and insulin-resistance when injected into germ-free mouse models.[72] A more recent study has uncovered a potentially contributing role for Enterobacter cloacae B29 toward obesity and insulin resistance in a human patient.[73] The presumed mechanism for the association of endotoxin with obesity is that endotoxin induces an inflammation-mediated pathway accounting for the observed obesity and insulin resistance.[72] Bacterial genera associated with endotoxin-related obesity effects include Escherichia and Enterobacter.

Depression

There is experimental and observational evidence that LPS might play a role in depression. Administration of LPS in mice can lead to depressive symptoms, and there seem to be elevated levels of LPS in some people with depression. Inflammation may sometimes play a role in the development of depression, and LPS is pro-inflammatory.[9]

Cellular senescence

Inflammation induced by LPS can induce cellular senescence, as has been shown for the lung epithelial cells and microglial cells (the latter leading to neurodegeneration).[10]

Role as contaminant in biotechnology and research

Lipopolysaccharides are frequent contaminants in plasmid DNA prepared from bacteria or proteins expressed from bacteria, and must be removed from the DNA or protein to avoid contaminating experiments and to avoid toxicity of products manufactured using industrial fermentation.[74]

Ovalbumin is frequently contaminated with endotoxins. Ovalbumin is one of the extensively studied proteins in animal models and also an established model allergen for airway hyper-responsiveness (AHR). Commercially available ovalbumin that is contaminated with LPS can falsify research results, as it does not accurately reflect the effect of the protein antigen on animal physiology.[75]

In pharmaceutical production, it is necessary to remove all traces of endotoxin from drug product containers, as even small amounts of endotoxin will cause illness in humans. A depyrogenation oven is used for this purpose. Temperatures in excess of 300 °C are required to fully break down LPS.[76]

The standard assay for detecting presence of endotoxin is the Limulus Amebocyte Lysate (LAL) assay, utilizing blood from the Horseshoe crab (Limulus polyphemus).[77] Very low levels of LPS can cause coagulation of the limulus lysate due to a powerful amplification through an enzymatic cascade. However, due to the dwindling population of horseshoe crabs, and the fact that there are factors that interfere with the LAL assay, efforts have been made to develop alternative assays, with the most promising ones being ELISA tests using a recombinant version of a protein in the LAL assay, Factor C.[78]

See also

References

  1. ^ Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H, et al. (February 1994). "Bacterial endotoxin: molecular relationships of structure to activity and function". FASEB Journal. 8 (2): 217–225. doi:10.1096/fasebj.8.2.8119492. PMID 8119492. S2CID 28156137.
  2. ^ a b c Avila-Calderón ED, Ruiz-Palma MD, Aguilera-Arreola MG, Velázquez-Guadarrama N, Ruiz EA, Gomez-Lunar Z, et al. (2021). "Outer Membrane Vesicles of Gram-Negative Bacteria: An Outlook on Biogenesis". Frontiers in Microbiology. 12: 557902. doi:10.3389/fmicb.2021.557902. PMC 7969528. PMID 33746909.
  3. ^ Höfte H, de Greve H, Seurinck J, Jansens S, Mahillon J, Ampe C, et al. (December 1986). "Structural and functional analysis of a cloned delta endotoxin of Bacillus thuringiensis berliner 1715". European Journal of Biochemistry. 161 (2): 273–280. doi:10.1111/j.1432-1033.1986.tb10443.x. PMID 3023091.
  4. ^ a b Roth J, Blatteis CM (October 2014). "Mechanisms of fever production and lysis: lessons from experimental LPS fever". Comprehensive Physiology. 4 (4): 1563–1604. doi:10.1002/cphy.c130033. ISBN 978-0-470-65071-4. PMID 25428854.
  5. ^ a b c d Kellum JA, Ronco C (October 2023). "The role of endotoxin in septic shock". Crit Care. 27 (1): 400. doi:10.1186/s13054-023-04690-5. PMC 10585761. PMID 37858258.
  6. ^ Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. (February 2013). "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012". Critical Care Medicine. 41 (2): 580–637. doi:10.1097/CCM.0b013e31827e83af. PMID 23353941. S2CID 34855187.
  7. ^ a b c d e f g h i j k l m n Moran AP, Prendergast MM, Appelmelk BJ (December 1996). "Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease". FEMS Immunology and Medical Microbiology. 16 (2): 105–115. doi:10.1016/s0928-8244(96)00072-7. PMID 8988391.
  8. ^ a b Moreno-Navarrete JM, Ortega F, Serino M, Luche E, Waget A, Pardo G, et al. (November 2012). "Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance". International Journal of Obesity. 36 (11): 1442–1449. doi:10.1038/ijo.2011.256. PMID 22184060.
  9. ^ a b Lasselin J, Schedlowski M, Karshikoff B, Engler H, Lekander M, Konsman JP (August 2020). "Comparison of bacterial lipopolysaccharide-induced sickness behavior in rodents and humans: Relevance for symptoms of anxiety and depression". Neuroscience and Biobehavioral Reviews. 115: 15–24. doi:10.1016/j.neubiorev.2020.05.001. PMID 32433924. S2CID 218665128.
  10. ^ a b Wei W, Ji S (December 2018). "Cellular senescence: Molecular mechanisms and pathogenicity". Journal of Cellular Physiology. 233 (12): 9121–9135. doi:10.1002/jcp.26956. PMID 30078211. S2CID 51924586.
  11. ^ Parija SC (1 January 2009). Textbook of Microbiology & Immunology. India: Elsevier. ISBN 978-8131221631.
  12. ^ Kulp A, Kuehn MJ (2010). "Biological functions and biogenesis of secreted bacterial outer membrane vesicles". Annual Review of Microbiology. 64: 163–184. doi:10.1146/annurev.micro.091208.073413. PMC 3525469. PMID 20825345.
  13. ^ Zhang G, Meredith TC, Kahne D (December 2013). "On the essentiality of lipopolysaccharide to Gram-negative bacteria". Current Opinion in Microbiology. 16 (6): 779–785. doi:10.1016/j.mib.2013.09.007. PMC 3974409. PMID 24148302.
  14. ^ Kukkonen M, Korhonen TK (July 2004). "The omptin family of enterobacterial surface proteases/adhesins: from housekeeping in Escherichia coli to systemic spread of Yersinia pestis". International Journal of Medical Microbiology. 294 (1): 7–14. doi:10.1016/j.ijmm.2004.01.003. PMID 15293449.
  15. ^ a b Galanos C, Freudenberg MA (1993). "Bacterial endotoxins: biological properties and mechanisms of action". Mediators Inflamm. 2 (7): S11-16. doi:10.1155/S0962935193000687. PMC 2365449. PMID 18475562.
  16. ^ Raetz CR, Whitfield C (2002). "Lipopolysaccharide endotoxins". Annual Review of Biochemistry. 71: 635–700. doi:10.1146/annurev.biochem.71.110601.135414. PMC 2569852. PMID 12045108.
  17. ^ Rittig MG, Kaufmann A, Robins A, Shaw B, Sprenger H, Gemsa D, et al. (December 2003). "Smooth and rough lipopolysaccharide phenotypes of Brucella induce different intracellular trafficking and cytokine/chemokine release in human monocytes". Journal of Leukocyte Biology. 74 (6): 1045–1055. doi:10.1189/jlb.0103015. PMID 12960272.
  18. ^ Tsujimoto H, Gotoh N, Nishino T (December 1999). "Diffusion of macrolide antibiotics through the outer membrane of Moraxella catarrhalis". Journal of Infection and Chemotherapy. 5 (4): 196–200. doi:10.1007/s101560050034. PMID 11810516. S2CID 2742306.
  19. ^ Hershberger C, Binkley SB (April 1968). "Chemistry and metabolism of 3-deoxy-D-mannooctulosonic acid. I. Stereochemical determination". The Journal of Biological Chemistry. 243 (7): 1578–1584. doi:10.1016/S0021-9258(18)93581-7. PMID 4296687.
  20. ^ Tzeng YL, Datta A, Kolli VK, Carlson RW, Stephens DS (May 2002). "Endotoxin of Neisseria meningitidis composed only of intact lipid A: inactivation of the meningococcal 3-deoxy-D-manno-octulosonic acid transferase". Journal of Bacteriology. 184 (9): 2379–2388. doi:10.1128/JB.184.9.2379-2388.2002. PMC 134985. PMID 11948150.
  21. ^ Khan MM, Ernst O, Sun J, Fraser ID, Ernst RK, Goodlett DR, Nita-Lazar A (August 2018). "Mass Spectrometry-based Structural Analysis and Systems Immunoproteomics Strategies for Deciphering the Host Response to Endotoxin". Journal of Molecular Biology. 430 (17): 2641–2660. doi:10.1016/j.jmb.2018.06.032. PMID 29949751. S2CID 49481716.
  22. ^ a b c d Kilár A, Dörnyei Á, Kocsis B (2013). "Structural characterization of bacterial lipopolysaccharides with mass spectrometry and on- and off-line separation techniques". Mass Spectrometry Reviews. 32 (2): 90–117. Bibcode:2013MSRv...32...90K. doi:10.1002/mas.21352. PMID 23165926.
  23. ^ Munford R, Lu M, Varley AW (2009). Chapter 2 Kill the Bacteria…and Also Their Messengers?. Advances in Immunology. Vol. 103. pp. 29–48. doi:10.1016/S0065-2776(09)03002-8. ISBN 9780123748324. PMC 2812913. PMID 19755182.
  24. ^ Bilski J, Mazur-Bialy A, Wojcik D, Zahradnik-Bilska J, Brzozowski B, Magierowski M, et al. (2017). "The Role of Intestinal Alkaline Phosphatase in Inflammatory Disorders of Gastrointestinal Tract". Mediators of Inflammation. 2017: 9074601. doi:10.1155/2017/9074601. PMC 5339520. PMID 28316376.
  25. ^ Bates JM, Akerlund J, Mittge E, Guillemin K (December 2007). "Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota". Cell Host & Microbe. 2 (6): 371–382. doi:10.1016/j.chom.2007.10.010. PMC 2730374. PMID 18078689.
  26. ^ Alam SN, Yammine H, Moaven O, Ahmed R, Moss AK, Biswas B, et al. (April 2014). "Intestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens". Annals of Surgery. 259 (4): 715–722. doi:10.1097/sla.0b013e31828fae14. PMC 3855644. PMID 23598380.
  27. ^ Lallès JP (February 2014). "Intestinal alkaline phosphatase: novel functions and protective effects". Nutrition Reviews. 72 (2): 82–94. doi:10.1111/nure.12082. PMID 24506153.
  28. ^ Wang X, Quinn PJ (April 2010). "Lipopolysaccharide: Biosynthetic pathway and structure modification". Progress in Lipid Research. 49 (2): 97–107. doi:10.1016/j.plipres.2009.06.002. PMID 19815028.
  29. ^ a b Ruiz N, Kahne D, Silhavy TJ (September 2009). "Transport of lipopolysaccharide across the cell envelope: the long road of discovery". Nature Reviews. Microbiology. 7 (9): 677–683. doi:10.1038/nrmicro2184. PMC 2790178. PMID 19633680.
  30. ^ Romano KP, Hung DT (March 2023). "Targeting LPS biosynthesis and transport in gram-negative bacteria in the era of multi-drug resistance". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1870 (3): 119407. doi:10.1016/j.bbamcr.2022.119407. PMC 9922520. PMID 36543281.
  31. ^ Sherman DJ, Xie R, Taylor RJ, George AH, Okuda S, Foster PJ, et al. (February 2018). "Lipopolysaccharide is transported to the cell surface by a membrane-to-membrane protein bridge". Science. 359 (6377): 798–801. Bibcode:2018Sci...359..798S. doi:10.1126/science.aar1886. PMC 5858563. PMID 29449493.
  32. ^ Pahil KS, Gilman MS, Baidin V, Clairfeuille T, Mattei P, Bieniossek C, et al. (January 2024). "A new antibiotic traps lipopolysaccharide in its intermembrane transporter". Nature. 625 (7995): 572–577. Bibcode:2024Natur.625..572P. doi:10.1038/s41586-023-06799-7. PMC 10794137. PMID 38172635.
  33. ^ Zampaloni C, Mattei P, Bleicher K, Winther L, Thäte C, Bucher C, et al. (January 2024). "A novel antibiotic class targeting the lipopolysaccharide transporter". Nature. 625 (7995): 566–571. Bibcode:2024Natur.625..566Z. doi:10.1038/s41586-023-06873-0. PMC 10794144. PMID 38172634.
  34. ^ Marshall JC (2005). "Lipopolysaccharide: an endotoxin or an exogenous hormone?". Clin Infect Dis. 41 (S7): S470–80. doi:10.1086/432000. PMID 16237650.
  35. ^ Abbas A (2006). Basic Immunology. Elsevier. ISBN 978-1-4160-2974-8.
  36. ^ Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. (December 1998). "Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene". Science. 282 (5396): 2085–2088. Bibcode:1998Sci...282.2085P. doi:10.1126/science.282.5396.2085. PMID 9851930.
  37. ^ "The 2011 Nobel Prize in Physiology or Medicine - Press Release". www.nobelprize.org. Archived from the original on 23 March 2018. Retrieved 28 April 2018.
  38. ^ Li Y, Deng SL, Lian ZX, Yu K (June 2019). "Roles of Toll-Like Receptors in Nitroxidative Stress in Mammals". Cells. 8 (6): 576. doi:10.3390/cells8060576. PMC 6627996. PMID 31212769.
  39. ^ a b c Brinkworth JF, Valizadegan N (2021). "Sepsis and the evolution of human increased sensitivity to lipopolysaccharide". Evol Anthropol. 30 (2): 141–157. doi:10.1002/evan.21887. PMID 33689211.
  40. ^ Warren HS, Fitting C, Hoff E, Adib-Conquy M, Beasley-Topliffe L, Tesini B, et al. (January 2010). "Resilience to bacterial infection: difference between species could be due to proteins in serum". The Journal of Infectious Diseases. 201 (2): 223–232. doi:10.1086/649557. PMC 2798011. PMID 20001600.
  41. ^ Reid RR, Prodeus AP, Khan W, Hsu T, Rosen FS, Carroll MC (July 1997). "Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide". Journal of Immunology. 159 (2): 970–975. doi:10.4049/jimmunol.159.2.970. PMID 9218618.
  42. ^ Boes M, Prodeus AP, Schmidt T, Carroll MC, Chen J (December 1998). "A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection". The Journal of Experimental Medicine. 188 (12): 2381–2386. doi:10.1084/jem.188.12.2381. PMC 2212438. PMID 9858525.
  43. ^ Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, et al. (April 2010). "Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection". Nature Medicine. 16 (4): 452–459. doi:10.1038/nm.2106. PMC 4229134. PMID 20208540.
  44. ^ a b Chastain EM, Miller SD (January 2012). "Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease". Immunological Reviews. 245 (1): 227–238. doi:10.1111/j.1600-065X.2011.01076.x. PMC 3586283. PMID 22168423.
  45. ^ Takizawa H, Fritsch K, Kovtonyuk LV, Saito Y, Yakkala C, Jacobs K, et al. (August 2017). "Pathogen-Induced TLR4-TRIF Innate Immune Signaling in Hematopoietic Stem Cells Promotes Proliferation but Reduces Competitive Fitness". Cell Stem Cell. 21 (2): 225–240.e5. doi:10.1016/j.stem.2017.06.013. PMID 28736216.
  46. ^ Lohmann KL, Vandenplas ML, Barton MH, Bryant CE, Moore JN (2007). "The equine TLR4/MD-2 complex mediates recognition of lipopolysaccharide from Rhodobacter sphaeroides as an agonist". Journal of Endotoxin Research. 13 (4): 235–242. doi:10.1177/0968051907083193. PMID 17956942. S2CID 36784237.
  47. ^ Netea MG, van Deuren M, Kullberg BJ, Cavaillon JM, Van der Meer JW (March 2002). "Does the shape of lipid A determine the interaction of LPS with Toll-like receptors?". Trends in Immunology. 23 (3): 135–139. doi:10.1016/S1471-4906(01)02169-X. PMID 11864841.
  48. ^ Seydel U, Oikawa M, Fukase K, Kusumoto S, Brandenburg K (May 2000). "Intrinsic conformation of lipid A is responsible for agonistic and antagonistic activity". European Journal of Biochemistry. 267 (10): 3032–3039. doi:10.1046/j.1432-1033.2000.01326.x. PMID 10806403.
  49. ^ Reeves PP, Wang L (2002). "Genomic Organization of LPS-Specific Loci". In Hacker J, Kaper JB (eds.). Pathogenicity Islands and the Evolution of Pathogenic Microbes. Current Topics in Microbiology and Immunology. Vol. 2. pp. 109–35. doi:10.1007/978-3-642-56031-6_7. ISBN 978-3-540-42682-0. PMID 12014174. 264.
  50. ^ Patil PB, Sonti RV (October 2004). "Variation suggestive of horizontal gene transfer at a lipopolysaccharide (lps) biosynthetic locus in Xanthomonas oryzae pv. oryzae, the bacterial leaf blight pathogen of rice". BMC Microbiology. 4: 40. doi:10.1186/1471-2180-4-40. PMC 524487. PMID 15473911.
  51. ^ a b c d e Yamasaki R, Kerwood DE, Schneider H, Quinn KP, Griffiss JM, Mandrell RE (December 1994). "The structure of lipooligosaccharide produced by Neisseria gonorrhoeae, strain 15253, isolated from a patient with disseminated infection. Evidence for a new glycosylation pathway of the gonococcal lipooligosaccharide". The Journal of Biological Chemistry. 269 (48): 30345–30351. doi:10.1016/S0021-9258(18)43819-7. PMID 7982947.
  52. ^ Howard MD, Cox AD, Weiser JN, Schurig GG, Inzana TJ (December 2000). "Antigenic diversity of Haemophilus somnus lipooligosaccharide: phase-variable accessibility of the phosphorylcholine epitope". Journal of Clinical Microbiology. 38 (12): 4412–4419. doi:10.1128/JCM.38.12.4412-4419.2000. PMC 87614. PMID 11101573.
  53. ^ Boonen B, Alpizar YA, Meseguer VM, Talavera K (August 2018). "TRP Channels as Sensors of Bacterial Endotoxins". Toxins. 10 (8): 326. doi:10.3390/toxins10080326. PMC 6115757. PMID 30103489.
  54. ^ Meseguer V, Alpizar YA, Luis E, Tajada S, Denlinger B, Fajardo O, et al. (20 January 2014). "TRPA1 channels mediate acute neurogenic inflammation and pain produced by bacterial endotoxins". Nature Communications. 5: 3125. Bibcode:2014NatCo...5.3125M. doi:10.1038/ncomms4125. PMC 3905718. PMID 24445575.
  55. ^ Soldano A, Alpizar YA, Boonen B, Franco L, López-Requena A, Liu G, et al. (June 2016). "Gustatory-mediated avoidance of bacterial lipopolysaccharides via TRPA1 activation in Drosophila". eLife. 5. doi:10.7554/eLife.13133. PMC 4907694. PMID 27296646.
  56. ^ Boonen B, Alpizar YA, Sanchez A, López-Requena A, Voets T, Talavera K (July 2018). "Differential effects of lipopolysaccharide on mouse sensory TRP channels". Cell Calcium. 73: 72–81. doi:10.1016/j.ceca.2018.04.004. PMID 29689522. S2CID 13681499.
  57. ^ Alpizar YA, Boonen B, Sanchez A, Jung C, López-Requena A, Naert R, et al. (October 2017). "TRPV4 activation triggers protective responses to bacterial lipopolysaccharides in airway epithelial cells". Nature Communications. 8 (1): 1059. Bibcode:2017NatCo...8.1059A. doi:10.1038/s41467-017-01201-3. PMC 5651912. PMID 29057902.
  58. ^ a b c d e f g Page MJ, Kell DB, Pretorius E (2022). "The Role of Lipopolysaccharide-Induced Cell Signalling in Chronic Inflammation". Chronic Stress. 6: 24705470221076390. doi:10.1177/24705470221076390. PMC 8829728. PMID 35155966.
  59. ^ Romaschin AD, Harris DM, Riberio MB, Paice J, Foster DM, Walker PM, Marshall JC (1998). "A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence". J Immunol Methods. 212 (2): 169–185. doi:10.1016/s0022-1759(98)00003-9. PMID 9672205.
  60. ^ Opal SM (2010). "Endotoxins and other sepsis triggers". Endotoxemia and Endotoxin Shock. Contributions to Nephrology. Vol. 167. pp. 14–24. doi:10.1159/000315915. ISBN 978-3-8055-9484-4. PMID 20519895.
  61. ^ a b Gomes JM, Costa JA, Alfenas RC (March 2017). "Metabolic endotoxemia and diabetes mellitus: A systematic review". Metabolism. 68: 133–144. doi:10.1016/j.metabol.2016.12.009. PMID 28183445.
  62. ^ a b Kallio KA, Hätönen KA, Lehto M, Salomaa V, Männistö S, Pussinen PJ (April 2015). "Endotoxemia, nutrition, and cardiometabolic disorders". Acta Diabetologica. 52 (2): 395–404. doi:10.1007/s00592-014-0662-3. PMID 25326898. S2CID 24020127.
  63. ^ Leskelä J, Toppila I, Härma MA, Palviainen T, Salminen A, Sandholm N, et al. (November 2021). "Genetic Profile of Endotoxemia Reveals an Association With Thromboembolism and Stroke". Journal of the American Heart Association. 10 (21): e022482. doi:10.1161/JAHA.121.022482. PMC 8751832. PMID 34668383.
  64. ^ Ceccanti M, Attili A, Balducci G, Attilia F, Giacomelli S, Rotondo C, et al. (October 2006). "Acute alcoholic hepatitis". Journal of Clinical Gastroenterology. 40 (9): 833–841. doi:10.1097/01.mcg.0000225570.04773.5d. PMID 17016141.
  65. ^ Parlesak A, Schäfer C, Schütz T, Bode JC, Bode C (May 2000). "Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease". Journal of Hepatology. 32 (5): 742–747. doi:10.1016/S0168-8278(00)80242-1. PMID 10845660.
  66. ^ a b c Stephens DS, Greenwood B, Brandtzaeg P (June 2007). "Epidemic meningitis, meningococcaemia, and Neisseria meningitidis". Lancet. 369 (9580): 2196–2210. doi:10.1016/S0140-6736(07)61016-2. PMID 17604802. S2CID 16951072.
  67. ^ Kellum JA, Formeck CL, Kernan KF, Gomez H, Carcillo JA (2022). "Subtypes and Mimics of Sepsis". Crit Care Clinics. 38 (2): 195–211. doi:10.1016/j.ccc.2021.11.013. PMID 35369943.
  68. ^ Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL (2006). "Colistin: The Re-Emerging Antibiotic for Multidrug-Resistant Gram-Negative Bacterial Infections". Lancet Infect Dis. 6 (9): 589–601. doi:10.1016/S1473-3099(06)70580-1. PMID 16931410.
  69. ^ Virzi GM, Mattiotti M, de Cal M, Ronco C, Zanella M, DeRosa S (2022). "Endotoxin in Sepsis: Methods for LPS Detection and the Use of Omics Techniques". Diagnostics. 13 (1): 79. doi:10.3390/diagnostics13010079. PMC 9818564. PMID 36611371.
  70. ^ Lepper PM, Schumann C, Triantafilou K, Rasche FM, Schuster T, Frank H, et al. (July 2007). "Association of lipopolysaccharide-binding protein and coronary artery disease in men". Journal of the American College of Cardiology. 50 (1): 25–31. doi:10.1016/j.jacc.2007.02.070. PMID 17601541. S2CID 12136094.
  71. ^ Ruiz AG, Casafont F, Crespo J, Cayón A, Mayorga M, Estebanez A, et al. (October 2007). "Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis". Obesity Surgery. 17 (10): 1374–1380. doi:10.1007/s11695-007-9243-7. PMID 18000721. S2CID 44494003.
  72. ^ a b Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. (July 2007). "Metabolic endotoxemia initiates obesity and insulin resistance". Diabetes. 56 (7): 1761–1772. doi:10.2337/db06-1491. PMID 17456850.
  73. ^ Fei N, Zhao L (April 2013). "An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice". The ISME Journal. 7 (4): 880–884. Bibcode:2013ISMEJ...7..880F. doi:10.1038/ismej.2012.153. PMC 3603399. PMID 23235292.
  74. ^ Wicks IP, Howell ML, Hancock T, Kohsaka H, Olee T, Carson DA (March 1995). "Bacterial lipopolysaccharide copurifies with plasmid DNA: implications for animal models and human gene therapy". Human Gene Therapy. 6 (3): 317–323. doi:10.1089/hum.1995.6.3-317. PMID 7779915.
  75. ^ Watanabe J, Miyazaki Y, Zimmerman GA, Albertine KH, McIntyre TM (October 2003). "Endotoxin contamination of ovalbumin suppresses murine immunologic responses and development of airway hyper-reactivity". The Journal of Biological Chemistry. 278 (43): 42361–42368. doi:10.1074/jbc.M307752200. PMID 12909619.
  76. ^ Komski L (16 December 2014). "The Detection of Endotoxins Via the LAL Test, the Chromogenic Method". Wako Chemicals USA, Inc. Archived from the original on 29 March 2015. Retrieved 14 March 2015.
  77. ^ Iwanaga S (May 2007). "Biochemical principle of Limulus test for detecting bacterial endotoxins". Proceedings of the Japan Academy. Series B, Physical and Biological Sciences. 83 (4): 110–119. Bibcode:2007PJAB...83..110I. doi:10.2183/pjab.83.110. PMC 3756735. PMID 24019589.
  78. ^ Ding JL, Ho B (August 2001). "A new era in pyrogen testing" (PDF). Trends in Biotechnology. 19 (8): 277–281. doi:10.1016/s0167-7799(01)01694-8. PMID 11451451. Archived from the original (PDF) on 2 January 2014. Retrieved 2 January 2014.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lipopolysaccharide&oldid=1241745838"